Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exenatide long-acting - AstraZeneca

Next Previous
Drug Profile

Exenatide long-acting - AstraZeneca

Alternative Names: Bydureon; BYDUREON BCise; Bydureon Pen; Byetta LAR; Exenatide extended-release for injectable suspension; Exenatide LAR; Exenatide once-weekly suspension; Ready to Use Exenatide Once Weekly

Latest Information Update: 18 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amylin Pharmaceuticals
  • Developer AstraZeneca; Eli Lilly and Company; University Medical Center Hamburg-Eppendorf
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II Obesity

Most Recent Events

  • 18 Nov 2025 Launched for Type 2 diabetes mellitus in Malaysia, Spain, Belgium, Greece, France, Poland (SC)
  • 17 Jul 2025 Withdrawn for Type 2 diabetes mellitus in New Zealand (SC)
  • 01 Mar 2025 Withdrawn for Type 2 diabetes mellitus in Denmark (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top